Scholarlink

Purpose <p>To evaluate whether personalized lung mass improves pre-treatment lung dose estimation accuracy compared to the 1000-g lung model, using post-treatment <sup>90</sup>Y PET/CT as the reference. Sex-specific anatomical differences and dosimetric factors associated with radiation pneumonitis (RP) were also explored.</p> Materials and methods <p>A retrospective analysis was conducted on 100 patients treated with <sup>90</sup>Y radioembolization from 2018 to 2025. Pre-treatment lung dose estimates were derived using both the standard 1000-g lung mass model and CT-based personalized lung mass. Post-treatment lung absorbed doses were quantified via <sup>90</sup>Y PET/CT. Dosimetric and clinical variables were compared between patients with and without RP, and sex-specific differences in lung anatomy and dose distribution were evaluated.</p> Results <p>The mean lung mass (760.11 ± 144.89&#xa0;g) was significantly lower than the 1000-g model (<i>P</i> &lt; 0.001). Two patients (2%) developed RP, and both had baseline lung metastases (28% overall). Although limited by the small number of events, the RP group showed a trend toward higher median administered activity (4425&#xa0;MBq [range, 3000–5800&#xa0;MBq] vs. 1300&#xa0;MBq [range, 400–4900&#xa0;MBq]) and lung absorbed dose, whereas no similar trend was observed for lung shunt fraction (LSF) (7.6% [range, 5.1–10.0%] vs. 4.3% [range, 1.0–14.5%]). Personalized lung dose showed a stronger correlation with <sup>90</sup>Y PET/CT than the 1000-g model (<i>r</i> = 0.678 vs. <i>r</i> = 0.612; <i>P</i> = 0.009), while LSF showed no correlation (<i>r</i> = 0.150). Sex-based dose differences seen with the 1000-g model were absent with personalized lung mass, which showed significantly lower lung mass in females (810.78 ± 126.21&#xa0;g vs. 636.05 ± 109.33&#xa0;g, <i>P</i> &lt; 0.001).</p> Conclusion <p>Personalized dosimetry improves predictive accuracy and mitigates sex-related dosimetric bias, suggesting CT-derived lung mass should be considered to optimize <sup>90</sup>Y radioembolization precision. Given our limited sample size, the association between pre-existing lung metastases and RP warrants further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Personalized lung dosimetry evaluated by 90Y PET/CT in radioembolization: dosimetric correlations and exploratory observations on radiation pneumonitis

  • 期刊论文

  • 发表日期：

    2026年7月7日

查看全文
  • Yi-Chieh Chen,
  • Po-Chin Liang,
  • Chih-Horng Wu,
  • Kao-Lang Liu,
  • Hui-Min Lu,
  • Ting-Yen Lee,
  • Shinn-Forng Peng,
  • Mei-Fang Cheng

摘要

Purpose

To evaluate whether personalized lung mass improves pre-treatment lung dose estimation accuracy compared to the 1000-g lung model, using post-treatment 90Y PET/CT as the reference. Sex-specific anatomical differences and dosimetric factors associated with radiation pneumonitis (RP) were also explored.

Materials and methods

A retrospective analysis was conducted on 100 patients treated with 90Y radioembolization from 2018 to 2025. Pre-treatment lung dose estimates were derived using both the standard 1000-g lung mass model and CT-based personalized lung mass. Post-treatment lung absorbed doses were quantified via 90Y PET/CT. Dosimetric and clinical variables were compared between patients with and without RP, and sex-specific differences in lung anatomy and dose distribution were evaluated.

Results

The mean lung mass (760.11 ± 144.89 g) was significantly lower than the 1000-g model (P < 0.001). Two patients (2%) developed RP, and both had baseline lung metastases (28% overall). Although limited by the small number of events, the RP group showed a trend toward higher median administered activity (4425 MBq [range, 3000–5800 MBq] vs. 1300 MBq [range, 400–4900 MBq]) and lung absorbed dose, whereas no similar trend was observed for lung shunt fraction (LSF) (7.6% [range, 5.1–10.0%] vs. 4.3% [range, 1.0–14.5%]). Personalized lung dose showed a stronger correlation with 90Y PET/CT than the 1000-g model (r = 0.678 vs. r = 0.612; P = 0.009), while LSF showed no correlation (r = 0.150). Sex-based dose differences seen with the 1000-g model were absent with personalized lung mass, which showed significantly lower lung mass in females (810.78 ± 126.21 g vs. 636.05 ± 109.33 g, P < 0.001).

Conclusion

Personalized dosimetry improves predictive accuracy and mitigates sex-related dosimetric bias, suggesting CT-derived lung mass should be considered to optimize 90Y radioembolization precision. Given our limited sample size, the association between pre-existing lung metastases and RP warrants further investigation.